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Abstract 
Background: Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) hold promise for 
assessment of drug-induced arrhythmias and are being considered for use under the Comprehensive in 
Vitro Proarrhythmia Assay (CiPA).  
Methods and Results: We studied the effects of 26 drugs and 3 drug combinations on two commercially 
available iPSC-CM types using high-throughput voltage-sensitive dye (VSD) and microelectrode-array 
(MEA) assays being studied for the Comprehensive in Vitro Proarrhythmia Assessment (CiPA) initiative 
and compared the results to clinical QT prolongation and torsade de pointes (TdP) risk. Concentration-
dependent analysis comparing iPSC-CMs to clinical trial results demonstrated good correlation between 
drug-induced APDc and FPDc prolongation and clinical trial QTc prolongation. Of 20 drugs studied that 
exhibit clinical QTc prolongation, 17 caused APDc prolongation (16 in Cor.4U and 13 in iCell 
cardiomyocytes) and 16 caused FPDc prolongation (16 in Cor.4U and 10 in iCell cardiomyocytes). Of 14 
drugs that cause TdP, arrhythmias occurred with 10 drugs. Lack of arrhythmic beating in iPSC-CMs for 
the 4 remaining drugs could be due to differences in relative levels of expression of individual ion 
channels.  iPSC-CMs responded consistently to hERG potassium channel blocking drugs (APD 
prolongation and arrhythmias) and calcium channel blocking drugs (APD shortening and prevention of 
arrhythmias), with a more variable response to late sodium current blocking drugs.  
Conclusion: Current results confirm the potential of iPSC-CMs for proarrhythmia prediction under CiPA, 
where iPSC-CM results would serve as a check to ion channel and in silico modeling prediction of 
proarrhythmic risk.  A multi-site validation study is warranted.  
Key Words  
CiPA, iPSC-CM, MEA, VSD, iCell, Cor.4U  
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Introduction 
 
           Between 1988 and 2009, 14 drugs were removed from the market worldwide as a result of their 
potential to induce life-threatening cardiac arrhythmias (Stockbridge et al. 2013). Regulatory agencies 
responded by requiring new drugs to be assessed for their ability to block the human ether-a-go-go 
(hERG) potassium channel and prolong the QT interval on the electrocardiogram (2005a; 2005b). While 
testing for hERG potassium channel inhibition and QT prolongation has prevented torsade de pointes 
(TdP) inducing drugs from reaching the market, other new drugs are dropped from development, 
sometimes inappropriately (Stockbridge et al. 2013). This may especially be true for the drugs that have 
multichannel effects, where the deleterious effect of hERG potassium channel block may be balanced out 
by the drug effect on inward currents, as is the case for several marketed drugs (e.g., verapamil also 
blocks L-type calcium current,  ranolazine blocks late sodium current) (Johannesen et al. 2014). This has 
been the driving factor for the development of a new Comprehensive in vitro Proarrhythmia Assay 
(CiPA) (Colatsky et al. 2016; Fermini et al. 2016; Sager et al. 2014).  
CiPA calls for a three-pronged preclinical approach. First, is to assess the effect of a drug on 
multiple isolated cardiac ion channels (e.g. hERG, L-type calcium, sodium) in patch clamp assays. 
Second, is to reconstruct the human ventricular action potential with in silico simulations to predict the 
proarrhythmic liability of the drug. Third, is to perform integrated cellular studies with human induced 
pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Complementary phase 1 electrocardiographic 
(ECG) data will then be collected with ECG biomarkers that can differentiate the effects of multichannel 
block (Sager et al. 2014).  
The goal of this study was to perform a thorough characterization of the current state of iPSC-
CMs technologies to predict drug pro-arrhythmic risk by assessing a large number of drugs in a blinded 
pre-planned study to advance regulatory science in this field. Discovery of reprogramming of somatic 
cells into pluripotent stem cells (Takahashi et al. 2007; Takahashi and Yamanaka 2006), and the 
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consequent development of the processes required to differentiate human iPSCs into functional human 
cardiomyocytes (Burridge et al. 2012; Kattman et al. 2011; Laflamme et al. 2007; Yang et al. 2008) 
created the basis for the growing use of iPSC-CMs for cardiotoxicity screening of drugs (Clements and 
Thomas 2014; Gibson et al. 2014; Guo et al. 2011; Harris et al. 2013; Ma et al. 2011; Navarrete et al. 
2013). Here we perform a comprehensive assessment of the proarrhythmic potential of 26 drugs in two 
commercially available iPSC-CM cell lines. The electrophysiology response of the iPSC-CMs is assessed 
with microelectrode arrays (MEA) and optical imaging of voltage sensitive dyes (VSD), technologies 
under consideration for inclusion in the CiPA screening paradigm due to promising preliminary 
correlation for clinically arrhythmogenic compounds (Clements and Thomas 2014; Harris et al. 2013). 
With these technologies, we focus on their ability to measure prolonged repolarization – action potential 
duration (APD) with VSD and field potential duration (FPD) by MEA – and detect the presence of 
arrhythmic events in vitro.  
Unique to this study, we compare the iPSC-CM results to the individual ion channel effects for 
the multiple ion channels being studied under CiPA and characterized expression of the corresponding 
encoding genes in two iPSC-CMs lines: rapidly activating delayed rectifier potassium current (IKr), 
encoded by hERG gene, L-type calcium current (ICaL), encoded by Cav1.2, and late sodium current 
(late-INa), encoded by Nav1.5, which are the 3 channels primarily affected by the drugs in this study 
(Crumb, Jr. et al. 2016). Gene expression data was also obtained for KCNQ1 gene, encoding slow 
voltage-gated potassium channel (IKs current). In addition, we performed a comparison between the 
concentration-dependent response of iPSC-CMs to 8 drugs and 3 drug combinations recently studied in 
clinical trials. Finally, we performed iPSC-CMs experiments with chronic exposure to drugs for up to 72 
hours.  
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Methods  
iPSC-CMs 
 Two commercially available iPSC-CMs cell lines were used in this study: iCell (Cellular 
Dynamics International) and Cor.4U (Axiogenesis AG). According to the manufacturers, iCell and 
Cor.4U were 100% and 95% pure iPSC-cardiomyocytes correspondingly, representing a mix of 
ventricular-, atrial-, and nodal-like cells (see Suppl. Methods for specific lot information).   
RNA Extraction and Real-time qRT-PCR 
Total RNAs of human adult left ventricle were purchased from Clontech (Mountain View, CA). 
Total RNAs from iCell and Cor.4U iPSC-CMs were prepared with miRNeasy Mini Kit (Qiagen, Hilden, 
Germany), and reverse transcribed into cDNA using RT² First Strand kits (SABiosciences/Qiagen). The 
Clontech total RNA was pooled from three different samples. The RNAs for iCells and Cor.4U 
cells were isolated from cells cultured in 3 different wells of single experiment. SYBR green-
based real-time qRT-PCR was performed on the CFX96 PCR detection system (Bio-Rad, Hercules, NC, 
USA) with gene-specific primers (SABiosciences), mRNA expression were normalized to β-actin. 
Manual Patch Clamp 
Stably transfected hERG, Nav1.5 cells (HEK-293) or Cav1.2 cells (CHO) were obtained from 
Cytocentrics Biosciences (Rostock, Germany). Cells were maintained according to the supplier 
instructions. The external solution had an ionic composition of (in mM): 137 NaCl, 4 KCl, 1.8 CaCl2, 1.2 
MgCl2, 11 dextrose, 10 HEPES, adjusted to a pH of 7.4 with NaOH. The internal (pipette) solution had 
an ionic composition of (in mM): 130 KCl; 1 MgCl2, 5 NaATP, 7 NaCl, 5 EGTA, 5 HEPES, pH=7.2 
using KOH. Currents were measured at 36 ± 1°C and 0.1Hz pacing rate using the whole-cell variant of 
the patch-clamp method (Crumb, Jr. et al. 1995). After rupture of the cell membrane, current amplitude 
and kinetics were allowed to stabilize (3-5 min) before recordings. Currents were elicited using a 
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ventricular action potential waveform (Johannesen et al. 2016)  (for hERG and Cav1.2) or a voltage 
waveform with a holding potential of -90 mV and pulsing to -15 mV for 40 ms (Nav1.5).  Late Nav1.5 
was elicited with the addition of 50 µM veratridine to the external solution and was measured at the end 
of the 40 ms pulse.  Relative block of current amplitude was measured as peak current amplitude after a 
steady-state effect had been reached in the presence of drug relative to current amplitude before drug 
addition.  
 
MEA and VSD recordings of drug-induced effects in iPSC-CMs  
100% confluent and synchronously beating Cor.4U and iCell cardiomyocytes monolayers were 
maintained according to manufacturer’s instructions (Suppl. Methods) and assayed using an MEA system 
(Maestro, Axion BioSystems, Atlanta, GA) and a VSD system (CellOPTIQ, Clyde Biosciences, UK) at 
37°C and 5% CO2. MEA and VSD recordings were performed 10-14 days post-thaw in iCell 
cardiomyocytes and 5-10 days post-thaw in Cor.4U cardiomyocytes. Drug effects were studied in serum-
free conditions at 4 doses (Suppl. Table I) by increasing drug concentration in the same well (N ≥3 wells) 
in acute experiments (up to 5h drug exposure time, Suppl. Fig. I) or by applying a single dose in each well 
in chronic experiments (up to 72h). Positive (dofetilide, lidocaine, and diltiazem) and negative (untreated 
and vehicle, 0.1% dimethyl sulfoxide) controls were repeated on each plate. Extracellular FPD and 
cellular membrane APD data was recorded and analyzed off-line using AxIS (Axion Biosystems) and 
CellOPTIQ (Clyde Biosciences) software, respectively. The Fridericia formula(Fridericia 2003) was used 
to correct APD and FPD dependence on beating rate (Suppl. Fig. II) (Johannesen et al. 2014). Vehicle- 
and baseline-corrected APD at 90% repolarization (∆∆APD90c) and field potential duration (∆∆FPDc) 
were calculated for the drugs at each dose and used to compare with the similarly calculated clinical 
∆∆QTc (Johannesen et al. 2014; Johannesen et al. 2016). Drug-induced arrhythmias were monitored with 
both platforms (Fig. 1). VSD-recorded arrhythmias were classified into 4 categories: Type A (single 
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notch), Type B (multiple notches), Type C (ectopic beat) and Type T (tachyarrhythmic). In the MEA 
dataset, corresponding arrhythmic events (Asakura et al. 2015) were collectively identified as “arrhythmic 
beats”, as shown in Fig. 1. In both MEA and VSD recordings, it was observed that some of the tested 
drugs inhibited spontaneous beating in the cells leading to a “quiescent” state (Q). The operators of MEA 
and VSD systems were blinded to treatment at the time of the recordings and data analysis. 
Statistical Analysis 
MEA and VSD data were analyzed using a linear-mixed effects model, where the data from 
untreated and vehicle control were combined and used as control. The differences for each dose were 
reported as the least-squares mean (95% confidence interval) of the difference between that dose and the 
corresponding time-matched control, using PROC MIXED in SAS 9.2 (SAS Institute, Cary, NC). A 
linear mixed-effects model was used to quantify the relationship between QTc and plasma drug 
concentration with concentration as a fixed effect and subject as a random effect on intercept and 
concentration.  
 
Results 
Baseline Electrophysiological Characteristics of iPSC-cardiomyocytes 
iPSC-CMs selected for this study exhibited spontaneous membrane depolarization. Baseline 
electrophysiological characteristics of spontaneous beating in Cor.4U and iCell cardiomyocytes are 
summarized in the Suppl. Table II. Briefly, Cor.4U beat faster (mean beat period of 1036±55 ms from 
MEA and 1271±244 ms from VSD) than iCells (mean beat period of 1578±109 ms from MEA and 
1876±240 ms from VSD). Cor.4U-cardiomyocytes also had shorter APD90c (299±17 ms in Cor.4U and 
463±31 ms in iCells) and FPDc (299±14 ms in Cor.4U and 468±42 ms in iCells).  However, as noted 
above, the beat rate and FPDc vs. APDc90 measurements for each cell type were very similar between 
MEA and VSD assays. Inter-assay and intra-assay co-efficient of variations are shown in Suppl. Table III.  
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Ion Channel Gene Expression 
The main ion channel currents (with corresponding gene and channel names) affected by the 
drugs selected for the current study were IKr (KCNH2; hERG), ICaL (CACNA1C; Cav1.2), INa 
(SCN5A; Nav1.5) and IKs (KCNQ1/minK; KvLQT1). NaV1.5 channel is responsible for both, peak 
sodium current, (peak-INa, not TTX-sensitive) and the late sodium current, (late-INa, TTX-sensitive). As 
we recently reported, the effect of the selected drugs on the other ion channels was minimal(Crumb, Jr. et 
al. 2016). We compared the expression of the genes encoding these four channels to the expression levels 
in adult primary human ventricular cardiomyocytes (Fig. 2). For outward IKr current, iCells had less and 
Cor4.U had more hERG expression than adult cardiomyocytes, while both iPSC-CM cell types had less 
KCNQ1 expression (outward IKs current). For inward currents (ICaL and INa), both iCells and Cor4.U 
had more Cav1.2 gene expression and less Nav1.5 gene expression than adult cardiomyocytes. The 
differences in hERG and Cav1.2 expression between iCells and Cor4.U are consistent with iCells having 
a longer APD than Cor4.U at baseline, as less outward current (IKr) and more inward current (ICaL) 
should both contribute to a longer APD. 
Effects of Dofetilide, Quinidine, Moxifloxacin, Ranolazine and Verapamil on iPSC-cardiomyocytes, 
and Comparison to Clinical QTc 
For these five drugs, we compared in vitro data with the information obtained in two recent FDA-
sponsored clinical trials (Johannesen et al. 2014; Johannesen et al. 2016). Representative MEA and VSD 
profiles in Cor.4U and iCell cardiomyocytes before and after drug addition for the five drugs are shown in 
Suppl. Fig. III. The iPSC-CM response (∆∆APDc and ∆∆FPDc, and arrhythmias) is shown in Fig. 3, 
along with the corresponding clinical QTc response and ion channel blockade dose-response relationships 
from patch clamp experiments with ion channels underlying 3 ventricular currents: hERG (IKr), Cav1.2 
(ICaL), and Nav1.5 (late-INa). Data for all drugs studied in the acute experiments is provided in Suppl. 
Fig. IV (A-Y).  
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Dofetilide, a drug associated with well-characterized clinical QTc prolongation and TdP (PFIZER 
1999), and which blocks hERG potassium channel exclusively in the tested dose range, induced a 
concentration-dependent prolongation of APDc and FPDc as well as arrhythmias in both Cor.4U and 
iCells. The degree of APDc and FPDc prolongation in iPSC-CMs was greater than that for clinical QTc. 
In vitro arrhythmias occurred at doses ≥2 nM, the approximate Cmax from the clinical trial (Johannesen 
et al. 2014). At the highest studied dofetilide dose (6 nM, ~3xCmax), both cell types exhibited arrhythmic 
beating in both VSD and MEA recordings. Of note, different patterns of arrhythmic beating occurred in 
the different cell types (see table inserts on Suppl. Fig. IV for the summary of observed arrhythmias). 
iCells first developed early afterdepolarizaions (EADs) (Figure 1: Type A arrhythmia), escalating to 
multiple EADs (Type B) and then ectopic beats (Type C), whereas Cor.4U cardiomyocytes preferentially 
developed tachyarrhythmic behavior (Type T arrhythmia).  
Like dofetilide, quinidine is associated with clinical QTc prolongation and TdP (PHARM RES 
ASSOC 1999). Quinidine induced a dose-dependent increase in APDc and FPDc in both iCell and 
Cor.4U cardiomyocytes (Fig.3). No arrhythmias occurred at the first dose (300 nM), but at 900 nM 
(~clinical Cmax) arrhythmias were detected in both MEA and VSD signals for 100% (6/6) of wells 
containing iCells, but not for those with Cor.4U cardiomyocytes. At the highest studied dose (5.4 µM, or 
~6.4x Cmax), all wells of the iPSC-CMs showed either arrhythmias or a cessation of spontaneous beating. 
The patch clamp data supports that the effect of quinidine on iPSC-CMs results primarily from hERG 
potassium channel block in the studied concentration range.  
At standard clinical concentrations moxifloxacin induces ~5% hERG potassium channel block 
and 10 ms of QTc prolongation (Florian et al. 2011), and in our clinical study (Johannesen et al. 2016) a 
supratherapeutic dose of intravenous moxifloxacin caused a QTc prolongation of 30 ms. At similar 
concentrations, the iPSC cardiomyocytes did not show statistically significant APDc or FPDc 
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prolongation, but moxifloxacin caused concentration-dependent APDc and FPDc prolongation above this 
range (21-200 µM), and arrhythmias were detected in in both cell types at ~50 fold clinical Cmax. 
Ranolazine causes strong block of channels underlying both the IKr (hERG) and late-INa 
(Nav1.5) currents (Fig. 3), which likely explain its minimal clinical risk of TdP despite QTc prolongation 
(Antzelevitch et al. 2004; Chaitman et al. 2004; Gilead Sciences 2013). Ranolazine caused a dose-
dependent increase in APDc and FPDc in both iCell and Cor.4U cardiomyocytes (Fig. 3), but consistent 
with clinical observations did not induce any arrhythmias in iPSC-CMs at doses up to 15 µM (~8x 
Cmax). Arrhythmias were detected in 1 out of 3 replicates by MEA recordings at 23 µM (~12x Cmax). 
Of note, the similar levels of hERG potassium channel block induced by 2-3 nM dofetilide and 6.9 µM 
ranolazine (~52%) induced >200 ms of APDc and FPDc prolongation and multiple arrhythmic events in 
dofetilide-treated cells, but only APDc and FPDc prolongation (<150 ms) without arrhythmias in 
ranolazine-treated cells.  
Verapamil in particular represents a case where multichannel drug-induced effects likely underlie 
the clinical safety. Verapamil causes strong hERG potassium channel block, and even more potent L-type 
calcium channel block (Fig. 3).  Even at hERG channel block of ~75 %, no arrhythmias were observed in 
iPSC-CMs. The Cor.4U cells stopped beating at ≥150 nM, likely due to strong ICaL block. In iPSC-CMs, 
verapamil caused significant concentration-dependent APDc and FPDc shortening in both cell types, 
while no QTc shortening was observed in the clinical study (Johannesen et al. 2014). This is likely due to 
the greater sensitivity of iPSC-CMs to ICaL block, consistent higher expression of Cav1.2 compared to 
human adult left ventricle. The higher doses of verapamil studied in iPSC-CMs were also much greater 
than clinical concentrations. 
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Summary Results of 25 Drugs Studied in Acute Experiments 
 Figure 4 and 5 summarize effects of all drugs on APDc (Fig. 4) and FPDc (Fig. 5) for iCell and 
Cor.4U cardiomyocytes. The drugs are ordered from top to bottom from the most APDc and FPDc 
prolongation to the most APDc and FPDc shortening at the clinical Cmax concentration when averaged 
across the four combinations of platform and cell type. For each drug, the effect at clinical Cmax and the 
maximum effect observed at any concentration are shown. Of note, quinidine, dofetilide, quinine and 
ranolazine had the most APDc and FPDc prolongation at clinical concentrations, consistent with greatest 
hERG block at Cmax. Diltiazem and verapamil had the most APDc and FPDc shortening at clinical 
concentrations, consistent with substantial ICaL block. 
 Figure 6 shows the lowest concentration relative to clinical Cmax where cells exhibited 
arrhythmias and stopped beating. The drugs are ordered based on APDc and FPDc effects at Cmax as in 
Figures 4 and 5, and in general drugs with greater APDc and FPDc prolongation at Cmax became 
arrhythmic at lower concentrations. For example, quinidine, dofetilide and quinine all developed 
arrhythmias close to Cmax concentrations. At a given dose, Cor.4U cells were more likely to stop beating 
than iCells, however this was often at >50x Cmax concentrations.  
The majority of arrhythmias in iPSC-CMs occurred with 60-80% hERG channel block. This is 
illustrated in Suppl. Fig. V, which shows the amount of hERG block present at the drug concentration 
where arrhythmias first developed. Notable drugs that exhibited strong hERG channel block (i.e. >60%) 
at higher concentrations but did not develop arrhythmias include ritonavir, mibefradil, bepridil, 
chlorpromazine, amitriptyline, terfenadine, amiodarone, azithromycin and verapamil. With the exception 
of bepridil and azithromycin, all of those drugs caused Cav1.2 or Nav1.5 (late) block (>50%). This is 
consistent with ICaL and late-INa block preventing hERG-related EADs and arrhythmias. 
  
Comparison of acute effects of 25 drugs to FDA labels for QTc prolongation and TdP Risk 
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Of 17 drugs with an FDA label of QTc prolongation studied in the acute iPSC-CM experiments, 
14 caused APDc prolongation and 13 caused FPDc prolongation in at least one iPSC-CMs type (Table 1). 
None of the 6 drugs without QTc prolongation on the FDA label caused FPDc or APDc prolongation. 
Diltiazem and verapamil shortened FPDc and APDc in both cell types and mibefradil shortened FPDc and 
APDc in iCell cardiomyocytes at the higher drug doses.    
Of the 12 drugs with TdP risk indicated on FDA labels, arrhythmias were detected in at least one 
iPSC-CM type for 7 drugs for both platforms, but often at a concentration greater than standard clinical 
Cmax. Five drugs that have TdP risk on the FDA label, but did not cause arrhythmias in iPSC-CMs even 
at doses significantly exceeding clinical, were amiodarone, azithromycin, bepridil, chlorpromazine, and 
terfenadine. The absence of arrhythmias for amiodarone, chlorpromazine, and bepridil in iPSC-CMs may 
be related to potent ICaL block (Suppl. Fig. IV), and higher-than-native expression levels of Cav1.2 in 
iPSC-CMs (Fig. 2).   
Cibenzoline and sertindole have not been approved in the U.S., however published clinical data 
exists showing clinical QTc prolongation for both, and TdP risk for sertindole.(Redfern et al. 2003) 
Cibenzoline induced FPDc and APDc prolongation in at least one iPSC-CM type and caused arrhythmias 
in iCells, but not in Cor.4U cardiomyocytes. Sertindole did not affect iCells, but induced FPDc and APDc 
prolongation and arrhythmias with the VSD platform in Cor.4U cells.  
Of the 11 drugs that do not have TdP risk on the FDA label, arrhythmias were detected for only 2: 
by MEA with nilotinib for both cell types and by VSD for iCells, and for ranolazine in MEA for iCells. 
However this occurred only at concentrations exceeding clinical by 12 fold for ranolazine and 100 fold 
for nilotinib.  
Overall, iPSC-CMs assay demonstrated 100% specificity (none of the clinically safe drugs 
induced APD/FPD prolongation in the studied dose range), 79% sensitivity for Cor.4U cardiomyocytes 
on both platforms, 63% for iCells on VSD and 47% for iCell on MEA platform (see Suppl. Table IV for 
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details on sensitivity and specificity calculation). These results suggest that while the general response to 
the studied drugs in all 4 cell type/combinations were similar, there was variation between the two cell 
types.  
 
Drug Combinations – hERG, late sodium and calcium channel block 
Co-application of drugs that block outward ionic currents (i.e. late-INa or ICaL) to balance QTc 
prolongation due to hERG blockade was tested in our recent clinical study (Johannesen et al. 2016). To 
see whether such effects could be observed in vitro, we studied the ability of the late-INa blockers 
lidocaine and mexiletine and ICaL blocker diltiazem to remediate the effect of IKr block from dofetilide 
and moxifloxacin in iPSC-CMs. Diltiazem caused substantial reversal of moxifloxacin-induced APDc 
and FPDc prolongation, and eliminated arrhythmias (Fig. 7). This effect did not occur in the clinical 
study; but interpretation there was confounded by the accumulation of a moxifloxacin metabolite 
(Johannesen et al. 2016). Both late-INa current blockers substantially shortened QTc prolongation from 
dofetilide in our recent clinical study (Johannesen et al. 2016). In iPSC-CMs, late-INa block did not cause 
consistent shortening of APDc or FPDc or elimination of arrhythmias, although this did occur with some 
combinations of cell type/platform (Suppl. Fig. VI). Lidocaine and mexiletine also had little effect on 
APDc or FPDc on their own (Suppl. Fig III), which may be due to lower expression of Nav1.5 in iPSC-
CM vs. adult left ventricle (Fig. 2).  
 
Chronic Effects 
The stability of the spontaneous beating phenotype in cultures of iPSC-CMs (Guo et al. 2013) 
allows prolonged drug exposure to be tested, a scenario that more closely parallels the repeated clinical 
dosing of most drugs. We thus studied the effects of 6 drugs on iPSC-CMs during chronic exposures: 72 
hours post-dose in the MEA platform (Fig. 8) and 24 hours post-dose with the VSD platform (Suppl. Fig. 
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VII). Chronic effects of the drugs beyond 24 hours were not studied with VSD platform to avoid repeated 
cell staining required for the longer term recordings. Results were consistent between MEA and VSD 
platform at the 24 h for the studied drugs. Pentamidine, dofetilide, amiodarone, and nilotinib generally 
caused progressively increasing APDc and FPDc over the course of the exposure, and the rate of change 
generally increased with dose (Fig. 8). An exception for these compounds was that prolongation of FPDc 
by dofetilide showed no time dependence for Cor.4U cells.  It is notable that amiodarone did not affect 
APDc in acute experiments, but induced APDc prolongation in both cell types after 24 hours.  Effects of 
diltiazem and lidocaine on APDc or FPDc had no time dependence in these experiments in either cell type 
and diltiazem-induced ∆∆FPDc shortening decreased after longer exposure (24-72h) in both cell types 
(data not shown).  
 
Discussion  
This study provides a comprehensive assessment of electrophysiology and pharmacodynamic 
responses of two commercially-available types of human iPSC-CMs in high-throughput assays, with 
quantitative comparisons to data for block of isolated ion channels and effects on clinical QTc. This type 
of mechanistic multiparameter characterization is critical for potential regulatory implementation of 
iPSC-CMs under a CiPA paradigm (Colatsky et al. 2016; Fermini et al. 2016; Sager et al. 2014). We 
observed concentration-dependent responses of both APDc and FPDc similar to clinical QTc prolongation 
for a series of drugs in recent FDA-sponsored clinical studies(Johannesen et al. 2014; Johannesen et al. 
2016). For some drugs (e.g. dofetilide and quinidine), the prolongation was greater in iPSC-CMs 
compared to clinical QTc prolongation. In addition, iPSC-CM arrhythmias developed at or near clinical 
concentrations (Fig. 6), consistent with the known torsade de pointes risk of dofetilide and quinidine 
(Kolb et al. 2008; Nagra et al. 2005; Reiffel 2005; Wroblewski et al. 2012).  
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An advantage of our study is the approach that was taken to drug dose selection. Whereas many 
previous studies test drugs in a pre-specified dose range regardless of the individual drug potency or 
clinical use, the lowest dose for each drug in our study was generally set to the clinical Cmax and then 
increased in intervals informed by pre-existing literature on individual ion channel block (Kramer et al. 
2013). Because significant variability in assay conditions exists in the literature, we report comparisons to 
manual patch experiments at physiological conditions using the same protocols for 25 drugs tested in the 
iPSC-CM experiments(Crumb, Jr. et al. 2016). The ion channel data support that block of hERG, Cav1.2 
and Nav1.5 (for late-INa) are most important for predicting TdP risk. In general, strong hERG block 
causes EADs and arrhythmias, while multichannel block involving Cav1.2 and Nav1.5 can prevent 
arrhythmias due to hERG blockade. Above a certain threshold for extreme hERG block (~75% block), 
arrhythmias or cessation of beating often develop even with multichannel block, except for instances of 
extremely strong Cav1.2 block (e.g. verapamil).  
While our primary focus was on the potential for drugs to acutely induce prolongation of the 
action potential, for a subset of drugs we also monitored APDc and FPDc during sustained chronic 
exposures lasting 1 (VSD) or 3 (MEA) days, which may more closely approximate clinical exposure for 
many drugs.  For 4 drugs (pentamidine, nilotinib, dofetilide, and amiodarone) we observed progressive 
increases during the exposure period in APDc and FPDc beyond values obtained for acute exposure. For 
pentamidine, this effect is consistent with the previously-described interruption of the trafficking of hERG 
potassium channels to the cell membrane (Kuryshev et al. 2005). The effect of nilotinib on spontaneous 
beating in IPSC-CMs has been described previously, and may be related to observed cytotoxicity during 
prolonged exposure (Doherty et al. 2013).  For amiodarone, no effect was observed for acute exposure, 
and evolution of APDc and FPDc prolongation could thus be due to conversion to the active desethyl 
metabolite (Talajic et al. 1987). Finally drug-induced increases in relative levels of channels carrying 
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inward currents may also explain progressively increasing APDc and FPDc for nilotinib and dofetilide 
(Lu et al. 2012; Talajic et al. 1987; Yang et al. 2014). 
Overall, of 20 drugs studied both in acute and chronic experiments (including pentamidine, not 
shown in Table 1) that exhibit clinical QTc prolongation, 17 caused APDc prolongation in at least one 
iPSC-CM type (16 in Cor.4U and 13 in iCell cardiomyocytes) and 16 caused FPDc prolongation in at 
least one iPSC-CM type (16 in Cor.4U and 10 in iCell cardiomyocytes). Of 14 drugs associated with TdP 
risk, arrhythmias were observed for 10 drugs in acute or chronic (amiodarone, pentamidine) experiments 
in at least one cell type-assay combination. Lack of arrhythmic beating in iPSC-CMs for the four 
remaining drugs associated with clinical TdP (bepridil, chlorpromazine, terfenadine, and azithromyocin), 
could be due to differences in relative levels of expression of individual ion channels. For example, higher 
expression of Cav1.2 in iPSC-CMs (vs adult ventricles) may increase the chance that the arrhythmic 
potential of hERG block is offset. Indeed, with the exception of azithromycin, each of these drugs shows 
blockade of Cav1.2 in the tested dose rage. Moreover, it should be noted that with the exception of 
bepridil, these drugs stopped spontaneous beating of iPSC-CMs at the highest studied doses.  
The correlation between drug effects in iPSC-CMs with clinical cardiotoxic effects was observed 
despite the relative immaturity of current iPSC-CMs previously discussed (Hoekstra et al. 2012; 
Knollmann 2013) and also confirmed in this study (immature phenotype, spontaneous membrane 
depolarizations, imperfect gene profiles as compared to adult cardiomyocytes). In addition to the ion 
channel encoding genes presented in this study, KCNJ2 encoding inward rectifier potassium channel 
protein Kir2.1 (IK1 current) is known to be particularly underexpressed in iPSC-CMs(Hoekstra et al. 
2012). Luckily, this channel is rarely affected by therapeutic drugs and the drugs in this study had a 
negligible effect on IK1 current (Crumb, Jr. et al. 2016). While human iPSC-CMs offer distinct 
advantages over isolated animal cardiomyocyte for drug safety assessment by providing an unlimited and 
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homogeneous source of human-derived cells, the development of more mature iPSC-CMs could 
potentially further improve predictability of the assays based on these cells.  
Study Limitations 
Execution of dose-response experiments through sequential addition of ascending drug doses to 
the same well (vs. parallel application of different doses to different wells) allows more data points to be 
obtained from a single well, and allows effects of all doses to be compared to a single baseline control 
reading. However, the longer time required to complete the full experiment increases the risk of 
confounding time-dependent drug effects. In addition, each dose was added every hour for the VSD 
study, and every 30 minutes for the MEA study, which could explain platform-specific differences for 
time-dependent drug effects.  Based on our results on negative controls and chronic experiments with a 
limited subset of the drugs, we estimate these effects to be minimal for many drugs, but we cannot 
completely rule it out for each individual drug. Furthermore, studying only 4 doses of each drug could not 
be optimal for detecting drug-induced arrhythmias, it is possible that the observed cessation of 
spontaneous beating at the highest doses would be preceded by arrhythmic events at a lower dose in an 
experiment with more drug concentrations assayed. It is likely that when using these methods in real life 
drug candidate screening a finer grid of doses would be assayed.  
Full control of the beating rate in spontaneously beating iPSC-CMs was not possible under 
physiological conditions (i.e. pacing at the rates below the intrinsic rate is not effective). To account for 
the dependence of action potential on the beating rate in iPSC-CMS an empirical formula, Bazet 
(Hernandez et al. 2016; Kim et al. 2010)or Fridericia (Lewis et al. 2015; Maddah et al. 2015)is usually 
used, that may not accurately correct for the rate dependence in the wide range of beating rates observed 
after drug treatments. The need for the forced rate correction would be overcome in a more mature and 
pure ventricular iPSC-CMs that did not demonstrate spontaneous depolarizations.  
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The parallel study of the drug effects on two iPSC-CMs lines studied using two different 
platforms would not be possible without some differences in the experimental design necessary to manage 
the performance of certain cell type/platform combinations. As a result, there were variations in how the 
experiments were performed for each of the combinations, including cell plating density, plate coating 
substrate, time in culture before drug studies began, cell culture media and the timing of the recordings. It 
is encouraging that despite the variations in the protocols the results of the study were largely consistent 
between 4 combinations of cell types and recording platforms. 
Each of the iPSC-CMs lines used in our study originated from a single healthy donor. A single 
batch of the cell lines was used for all of the experiments to minimize the variability. While improving the 
consistency of the results, this approach does not account for the genetic predisposition of individual 
patients that can play a pivotal role in defining the clinical risk of arrhythmia for individual patients. In 
addition, drug-induced TdP often occurs in patients with pre-existing cardiac disease. iPSC-CMs used in 
this study do not reflect patients with pre-existing cardiac disease.  
Finally, the chosen number of replicates of each drug concentration (3) represented a balance 
with the desire to test a large number of drugs (26) on two cell types and two different platforms. The 
goal of this study was to have a broad characterization of iPSC-CM physiology and pharmacology that 
can guide future work for best practices and verification under the CiPA initiative, where more replicates 
can be tested if required.  
 
Conclusions 
Concentration-dependent analysis of drug effects on spontaneous electrical activity in iPSC-CMs, 
using both VSD and MEA platforms, yielded good correlation between drug-induced APDc and FPDc 
prolongation and clinical QTc prolongation, and between the presence of in vitro and clinical arrhythmias, 
with some limitations and differences.  Spontaneous action or field potentials in  iPSC-CMs were 
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sensitive to hERG blocking drugs (causing APDc and FPDc prolongation and arrhythmias) and ICaL-
blocking drugs (causing APDc and FPDc shortening and prevention of hERG-related arrhythmias), with a 
more variable sensitivity to blockers of late-INa. The present results, in combination with those of other 
recent studies, highlight iPSC-CMs as a promising new in vitro technology that can be included in 
proarrhythmia assay paradigms, such as that proposed in CiPA. While some discrepancies exist between 
iPSC-CM assays and clinical experience, under CiPA they would be combined with patch clamp 
assessment of individual ion channels and in silico modeling. In combination, this is likely to be a 
substantial improvement in efficiency and predictivity over the present focus on hERG binding and 
assessment of clinical QTc prolongation late in drug development. An international multi-site validation 
study with standardized protocols is warranted. 
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Supplementary Data description 
 
1. Supplementary methods 
 Detailed protocols on iPSC-CMs plating and maintenance, MEA and VSD recordings 
protocols; 
2. Supplementary Tables 
Suppl. Table I: Cmax and drug doses selected for iPSC-CMs experiments 
Suppl. Table II: Baseline parameters characterizing spontaneous beating in iPSC-CMs 
Suppl. Table III: Inter-assay and intra-assay variation for MEA and VSD 
Suppl. Table IV: Sensitivity and specificity of the iPSC-CMs assay to predict clinical QTc 
prolongation 
3. Supplementary Figures 
Suppl. Fig. I: Experimental protocol for MEA and VSD recordings 
Suppl. Fig. II: APD and FPD rate-dependence correction with Fridericia formula 
Suppl. Fig. III: Representative VSD and MEA profiles for dofetilide, quinidine, 
moxifloxacin, ranolazine, and verapamil. 
Suppl. Fig. IV: Drug-induced effects on APDc  and FPDc in iPSC-CMs and drug-induced 
relative channel block 
Suppl. Fig. V: Minimum percent hERG block at which a drug induced arrhythmias in iPSC-
CMs 
Suppl. Fig. VI: Effect of drug combinations (dofetilide+lidocaine and dofetilide+mexiletine 
in iPS-CMs) 
Suppl. Fig. VII: Chronic effects of pentamidine, amiodarone, dofetilide and nilotinib in iCell 
and Cor.4U cardiomyoyctes in VSD assay 
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Figure Legends 
Fig. 1. Arrhythmias observed in iPSC-CMs  
The first five traces show VSD recordings of normal and arrhythmic iPSC-CM action potentials. 
Different types of arrhythmias are shown (A, B, C, and T). The last three traces represent normal 
MEA beating and two examples of MEA traces with arrhythmias: a notched repolarization 
waveform and ectopic beat.  
Fig. 2. iPSC-CM ion channel gene expression profiles  
Expression of the genes encoding four ion channels: SCN5A (Nav1.5), CACNA1C (Cav1.2), 
KCNH2 (hERG), and KCNQ1 in human primary adult cardiac tissue and human iPSC-CMs 
(normalized to adult primary levels). Data represent means ± SD for N=3 replicates. Stars 
indicate statistically significant differences (p<0.05). 
Fig. 3. Effect of dofetilide, quinidine, moxifloxacin, ranolazine and verapamil on iPSC-CM 
APDc, FPDc and clinical QTc 
For each drug, left panels show relative drug-induced channel block from patch clamp 
experiments, the error bars represent ± SE of mean percent channel block. The vertical lines 
represent clinical Cmax (solid line) and drug doses in iPSC-CMs experiments (dashed lines).  
The middle and right panels show drug-induced changes in APDc and FPDc in iCell (orange) 
and Cor.4U (gray), and clinical QTc (blue). 95% confidence intervals are shown as error bars in 
∆∆APDc and ∆∆FPDc and in gray shading for the clinical QTc data. The tables represent the 
number of wells in acute iPSC-CM experiments where drug-induced arrhythmic events or 
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cessation of spontaneous contractions (Q) were observed in MEA and VSD, along with the type 
(A, B, C, or T) of the arrhythmia (for VSD).  
Fig. 4. Acute effects of 25 drugs on FPDc in iCell and Cor.4U cardiomyocytes 
The two panels represent drug effects on FPDc in each cell type. The mean values for  ∆∆FPDc 
are shown with the error bars representing 95% CI of the calculated mean across replicates (solid 
error bars are used for p-value <0.05, and dotted error bars are used for p-value≥0.05). The effect 
on APDc/FPDc at clinical Cmax (green) and the maximum effect observed at any drug 
concentration (red) are shown for each drug. Note that only drug doses when FPD could be 
measured (i.e. cells were spontaneously beating and the induced arrhythmias did not interfere 
with the FPDc calculations) are included. The vertical black dotted lines represent 2 SD 
threshold calculated for the variability in FPDc for the vehicle control wells for each cell type. 
The drugs are ordered from top to bottom by the drugs having the most APDc/FPDc 
prolongation to the most APDc/FPDc shortening at the clinical Cmax concentration when 
averaged among the four combinations of platform and cell type.  
Fig. 5. Acute effects of 25 drugs on APD90c in iCell and Cor.4U cardiomyocytes 
The two panels represent drug effects on APD90c in each cell type. The mean values for 
∆∆APDc are shown with the error bars representing 95% CI of the calculated mean across 
replicates (solid error bars are used for p-value <0.05, and dotted error bars are used for p-
value≥0.05). The effect on APD90c at clinical Cmax (green) and the maximum effect observed 
at any drug concentration (red) are shown for each drug. Note that only drug doses when 
APD90c could be measured (i.e. cells were spontaneously beating and the induced arrhythmias 
did not interfere with the APD90c calculations) are included. The vertical black dotted lines 
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represent 2 SD threshold calculated for the variability in APD90c for the vehicle control wells 
for each cell type. The drugs are ordered from top to bottom by the drugs having the most 
APD90c/FPDc prolongation to the most APD90c/FPDc shortening at the clinical Cmax 
concentration when averaged among the four combinations of platform and cell type.  
Fig. 6. Drug induced arrhythmias/quiescence in iCell and Cor.4U cardiomyocytes 
The four panels represent drug-induced arrhythmias and inhibition of the spontaneous beating 
(quiescent) effects in each cell type-assay combination. The lowest drug concentration at which 
drug-induced arrhythmias (red crosses) or cessation of spontaneous beating (blue circles) is 
shown for each drug as number of folds of the clinical Cmax of that drug.  
Fig. 7. Diltiazem effect on moxifloxacin-induced APDc/FPDc prolongation and arrhythmias 
The four panels represent drug effects in each cell type/assay combination. Moxifloxacin was 
added to the iPSC-CMs at three different concentrations at the first dosing, then diltiazem was 
added in increasing concentrations at the three subsequent dosings while moxifloxacin 
concentration was maintained constant. The least-square means of drug-induced changes in 
FPDc and APD90c are shown with error bars representing 95% CI from the means. The symbols 
on the top of the graphs represent time points where either arrhythmias (open symbols) or 
inhibition of spontaneous beating (crosses) were observed. The color of the symbols corresponds 
to the color-coding of moxifloxacin concentrations (see the legend on the bottom of the plot).  
Fig. 8. Chronic effects of pentamidine, amiodarone, dofetilide and nilotinib on iCell and 
Cor.4U cardiomyocytes in MEA assay 
The mean drug-induced changes in FPDc are shown with error bars representing 95% CI from 
the least-square means of the differences. The symbols on the bottom of the graphs represent 
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time points where either arrhythmias (crosses) or inhibition of spontaneous beating (open circles) 
were observed. The color of these symbols corresponds to the color-coding of the drug 
concentrations (see the legend on the right side of each panel).  
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Tables 
Table 1. Comparison of acute drug-induced effects in iPSC-CMs with QTc and TdP 
information on the corresponding FDA drug label 
Drug 
Repolarization effect in iPS cells Arrhythmias induced in iPS 
∆∆FPDc 
Cor.4U 
∆∆FPDc 
iCell 
∆∆APDc 
Cor.4U 
∆∆APDc 
iCell 
MEA 
Cor.4
U 
MEA  
iCell 
VSD  
Cor.4U 
VSD 
iCell 
QT ↑and TdP on the FDA label 
Quinidine ↑ ↑ ↑ ↑ × × - × 
Dofetilide ↑ ↑ ↑ ↑ × × × × 
Quinine ↑ ↑ ↑ ↑ - × × × 
Propafenone ↑ ↑ ↑ ↑ - × - × 
Moxifloxacin ↑ ↑ ↑ ↑ × × × × 
Chloroquine ↑ ↑ ↑ ↑ × × × × 
Bepridil ↑ - ↑ ↑ - - - - 
Chlorpromazine - - ↑ - - - - - 
Terfenadine ↑ - ↑ ↑ - - - - 
Cisapride ↑ ↑ ↑ - × - - × 
Amiodarone ↑ - - - - - - - 
Azithromycin - ↓ - ↓ - - - - 
QT ↑, but no TdP on the FDA label 
Ranolazine ↑ ↑ ↑ ↑ - × - - 
Ritonavir ↑ - ↑ - - - - - 
Amitriptyline - - - - - - - - 
Nilotinib ↑ ↑ ↑ ↑ × × - × 
Toremifene - - - ↑ - - - - 
No QT ↑, nor TdP on the FDA label 
Lidocaine - - - - - - - - 
Mexiletine - - - - - - - - 
Mibefradil - ↓ - ↓ - - - - 
Diltiazem ↓ ↓ ↓ ↓ - - - - 
Verapamil ↓ ↓ ↓ ↓ - - - - 
Licarbazepine - - - - - - - - 
Not FDA-cleared* 
Cibenzoline ↑ - ↑ ↑ - × - × 
Sertindole ↑ - ↑ - - - × - 
* cibenzoline (QTc ↑), sertindole (QTc ↑, TdP)(Redfern et al. 2003)  
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Table 1. Twenty-five drugs studied in acute iPSC-CM experiments are divided into four 
categories based on the presence of QTc prolongation and TdP reports on the FDA-approved 
label. Symbol ↑ means that drug induced statistically significant (p-value<0.05) and above the 
threshold change in APDc or FPDc for at least one of the doses. The threshold for each cell type-
assay combination was set at the two standard deviations of the variability in APDc/FPDc 
measurements in the control (no drug) wells. Red shading represents the drugs that induced 
FPDc or APDc prolongation (↑) and green shading represents the drugs that shortened  FPDc or 
APDc (↓) or had no effect.  The cross symbol (×) means that the corresponding drug induced 
arrhythmias in at least 30% of the replicate wells.  
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Fig. 1. Arrhythmias observed in iPSC-CMs  
The first five traces show VSD recordings of normal and arrhythmic iPSC-CM action potentials. Different 
types of arrhythmias are shown (A, B, C, and T). The last three traces represent normal MEA beating and 
two examples of MEA traces with arrhythmias: a notched repolarization waveform and ectopic beat.  
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Fig. 2. iPSC-CM ion channel gene expression profiles  
Expression of the genes encoding four ion channels: SCN5A (Nav1.5), CACNA1C (Cav1.2), KCNH2 (hERG), 
and KCNQ1 in human primary adult cardiac tissue and human iPSC-CMs (normalized to adult primary 
levels). Data represent means ± SD for N=3 replicates. Stars indicate statistically significant differences 
(p<0.05).  
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Fig. 3. Effect of dofetilide, quinidine, moxifloxacin, ranolazine and verapamil on iPSC-CM APDc, FPDc and 
clinical QTc  
For each drug, left panels show relative drug-induced channel block from patch clamp experiments, the 
error bars represent ± SE of mean percent channel block. The vertical lines represent clinical Cmax (solid 
line) and drug doses in iPSC-CMs experiments (dashed lines).  The middle and right panels show drug-
induced changes in APDc and FPDc in iCell (orange) and Cor.4U (gray), and clinical QTc (blue). 95% 
confidence intervals are shown as error bars in ∆∆APDc and ∆∆FPDc and in gray shading for the clinical QTc 
data. The tables represent the number of wells in acute iPSC-CM experiments where drug-induced 
arrhythmic events or cessation of spontaneous contractions (Q) were observed in MEA and VSD, along with 
the type (A, B, C, or T) of the arrhythmia (for VSD).  
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Fig. 4. Acute effects of 25 drugs on FPDc in iCell and Cor.4U cardiomyocytes  
The two panels represent drug effects on FPDc in each cell type. The mean values for  ∆∆FPDc are shown 
with the error bars representing 95% CI of the calculated mean across replicates (solid error bars are used 
for p-value <0.05, and dotted error bars are used for p-value≥0.05). The effect on APDc/FPDc at clinical 
Cmax (green) and the maximum effect observed at any drug concentration (red) are shown for each drug. 
Note that only drug doses when FPD could be measured (i.e. cells were spontaneously beating and the 
induced arrhythmias did not interfere with the FPDc calculations) are included. The vertical black dotted lines 
represent 2 SD threshold calculated for the variability in FPDc for the vehicle control wells for each cell type. 
The drugs are ordered from top to bottom by the drugs having the most APDc/FPDc prolongation to the 
most APDc/FPDc shortening at the clinical Cmax concentration when averaged among the four combinations 
of platform and cell type.  
 
Fig. 4  
 at U
niversity of G
lasgow
 on N
ovem
ber 14, 2016
http://toxsci.oxfordjournals.org/
D
ow
nloaded from
 
216x258mm (300 x 300 DPI)  
 
 
 at U
niversity of G
lasgow
 on N
ovem
ber 14, 2016
http://toxsci.oxfordjournals.org/
D
ow
nloaded from
 
  
 
 
Fig. 5. Acute effects of 25 drugs on APD90c in iCell and Cor.4U cardiomyocytes  
The two panels represent drug effects on APD90c in each cell type. The mean values for ∆∆APDc are shown 
with the error bars representing 95% CI of the calculated mean across replicates (solid error bars are used 
for p-value <0.05, and dotted error bars are used for p-value≥0.05). The effect on APD90c at clinical Cmax 
(green) and the maximum effect observed at any drug concentration (red) are shown for each drug. Note 
that only drug doses when APD90c could be measured (i.e. cells were spontaneously beating and the 
induced arrhythmias did not interfere with the APD90c calculations) are included. The vertical black dotted 
lines represent 2 SD threshold calculated for the variability in APD90c for the vehicle control wells for each 
cell type. The drugs are ordered from top to bottom by the drugs having the most APD90c/FPDc 
prolongation to the most APD90c/FPDc shortening at the clinical Cmax concentration when averaged among 
the four combinations of platform and cell type.  
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Fig. 6. Drug induced arrhythmias/quiescence in iCell and Cor.4U cardiomyocytes  
The four panels represent drug-induced arrhythmias and inhibition of the spontaneous beating (quiescent) 
effects in each cell type-assay combination. The lowest drug concentration at which drug-induced 
arrhythmias (red crosses) or cessation of spontaneous beating (blue circles) is shown for each drug as 
number of folds of the clinical Cmax of that drug.  
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Fig. 7. Diltiazem effect on moxifloxacin-induced APDc/FPDc prolongation and arrhythmias  
The four panels represent drug effects in each cell type/assay combination. Moxifloxacin was added to the 
iPSC-CMs at three different concentrations at the first dosing, then diltiazem was added in increasing 
concentrations at the three subsequent dosings while moxifloxacin concentration was maintained constant. 
The least-square means of drug-induced changes in FPDc and APD90c are shown with error bars 
representing 95% CI from the means. The symbols on the top of the graphs represent time points where 
either arrhythmias (open symbols) or inhibition of spontaneous beating (crosses) were observed. The color 
of the symbols corresponds to the color-coding of moxifloxacin concentrations (see the legend on the 
bottom of the plot).  
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Fig. 8. Chronic effects of pentamidine, amiodarone, dofetilide and nilotinib on iCell and Cor.4U 
cardiomyocytes in MEA assay  
The mean drug-induced changes in FPDc are shown with error bars representing 95% CI from the least-
square means of the differences. The symbols on the bottom of the graphs represent time points where 
either arrhythmias (crosses) or inhibition of spontaneous beating (open circles) were observed. The color of 
these symbols corresponds to the color-coding of the drug concentrations (see the legend on the right side 
of each panel).  
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